Vivos Therapeutics (VVOS) Retained Earnings (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Retained Earnings data on file, last reported at -$133.0 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 218.3% year-over-year to -$133.0 million in Q1 2026; TTM through Mar 2026 was -$133.0 million, a 218.3% decrease from a year earlier, with the FY2025 full-year figure at $123.9 million, up 10.46% from the prior year.
• Retained Earnings for Q1 2026 stood at -$133.0 million, down from $123.9 million in the prior quarter.
• Over the last five years, Retained Earnings for VVOS reached as high as $123.9 million in Q4 2025 and fell as low as -$133.0 million in Q1 2026.
• Historically, Retained Earnings has averaged -$11.4 million across 5 years, with a median of -$73.4 million in 2022.
• Across the five-year window, Retained Earnings surged 311.68% in 2022 and slumped 218.3% in 2026, its largest moves.
• Year by year, Retained Earnings stood at $84.3 million in 2022, then sank by 210.42% to -$93.1 million in 2023, then surged by 220.52% to $112.1 million in 2024, then advanced by 10.46% to $123.9 million in 2025, then plunged by 207.41% to -$133.0 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$133.0 million in Q1 2026, $123.9 million in Q4 2025, and $121.0 million in Q3 2025.